Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

35.82USD
23 Feb 2017
Change (% chg)

$-0.15 (-0.42%)
Prev Close
$35.97
Open
$35.81
Day's High
$36.19
Day's Low
$35.67
Volume
1,706,138
Avg. Vol
2,330,867
52-wk High
$59.34
52-wk Low
$31.91

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000... (more)

Overall

Beta: 0.62
Market Cap(Mil.): $36,239.92
Shares Outstanding(Mil.): 1,014.36
Dividend: 0.34
Yield (%): 3.84

Financials

  TEVA.N Industry Sector
P/E (TTM): 228.38 28.90 29.71
EPS (TTM): 0.15 -- --
ROI: 0.53 13.43 12.94
ROE: 0.22 14.33 14.09

Teva settles 'vast majority' of lawsuits over generic Reglan

Teva Pharmaceutical Industries Ltd has agreed to settle the "vast majority" of the roughly 4,000 lawsuits it faced over its generic version of the heartburn drug Reglan, which has been linked to a serious neurological disorder.

Feb 17 2017

Marcato's McGuire criticizes Deckers' retail expansion: CNBC

NEW YORK Mick McGuire, founder of activist hedge fund Marcato Capital Management, told CNBC on Monday that Deckers Outdoor Corp had erred by investing significantly in physical retail stores.

Feb 13 2017

UPDATE 1-Marcato's McGuire criticizes Deckers' retail expansion -CNBC

NEW YORK, Feb 13 Mick McGuire, founder of activist hedge fund Marcato Capital Management, told CNBC on Monday that Deckers Outdoor Corp had erred by investing significantly in physical retail stores.

Feb 13 2017

BRIEF-Teva said to weigh options for branded generics to reduce debt- Bloomberg, citing sources

* Teva said to weigh options for branded generics to reduce debt - Bloomberg, citing sources

Feb 13 2017

Teva seeks CEO with pharma background to lead recovery efforts

TEL AVIV Teva Pharmaceutical Industries is seeking a new chief executive with deep drug industry experience, the Israel-based company said on Monday as it looks to restore confidence after a series of missteps and the departure of CEO Erez Vigodman.

Feb 13 2017

UPDATE 2-Teva seeks CEO with pharma background to lead recovery efforts

* Shares in New York up 4 percent in early trade (Recasts with comments about CEO, adds details from conference call, analyst)

Feb 13 2017

BRIEF-Teva board seeks new CEO with extensive pharma experience

* Teva chairman: board has begun search for new CEO with extensive pharmaceutical experience

Feb 13 2017

Teva Pharm Q4 profit, revenue beat expectations

TEL AVIV, Feb 13 Teva Pharmaceutical Industries reported better-than- expected fourth-quarter profit as sales were boosted by its $40.5 billion acquisition of Allergan's Actavis generic drug business on Aug. 2.

Feb 13 2017

BRIEF-Allergan says does not see U.S. tax reform in 2017

* Allergan CEO "We have a good report card for 2016 and a positive outlook for 2017 and beyond"

Feb 08 2017

Teva CEO exits in ongoing crisis of confidence at drugmaker

TEL AVIV Teva Pharmaceutical Industries was left without a permanent chief executive on Tuesday after Erez Vigodman stepped down, leaving new management to restore confidence in the world's biggest generic drugmaker after a series of missteps. | Video

Feb 07 2017

More From Around the Web

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF77.60 0.00
Biogen Inc (BIIB.OQ) $285.13 +0.38

Earnings vs. Estimates